Offering women further screening opportunities when they visit healthcare providers for breast cancer screening may significantly increase their participation and enable early diagnosis of other cancers, per clinical trial of more than 27,000 in Denm…
Offering women further screening opportunities when they visit healthcare providers for breast cancer screening may significantly increase their participation and enable early diagnosis of other cancers, per clinical trial of more than 27,000 in Denmark Credit: PDPics, Pixabay (CC0, https://creativecommons.org/publicdomain/zero/1.0/) Offering women further screening opportunities when they visit healthcare providers for breast cancer screening may […]
Offering women further screening opportunities when they visit healthcare providers for breast cancer screening may significantly increase their participation and enable early diagnosis of other cancers, per clinical trial of more than 27,000 in Denmark
Credit: PDPics, Pixabay (CC0, https://creativecommons.org/publicdomain/zero/1.0/)
Offering women further screening opportunities when they visit healthcare providers for breast cancer screening may significantly increase their participation and enable early diagnosis of other cancers, per clinical trial of more than 27,000 in Denmark
#####
In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004431
Article Title: Increasing coverage in cervical and colorectal cancer screening by leveraging attendance at breast cancer screening: A cluster-randomised, crossover trial
Author Countries: Denmark
Funding: The author(s) received no specific funding for this work.
Journal
PLoS Medicine
DOI
10.1371/journal.pmed.1004431
Method of Research
Observational study
Subject of Research
People
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Roche Diagnostics sponsored the Cobas 4800 HPV DNA tests in this study. According to the contract between Roche Diagnostics and the University Research Clinic for Cancer Screening, Randers Regional Hospital, Denmark, Roche Diagnostics had no influence on the scientific process and no editorial rights pertaining to this manuscript. MT, LKP and BA have participated in other studies with human papillomavirus (HPV) DNA tests sponsored by Roche Diagnostics. MT has received honoraria from Roche Diagnostics for lectures on HPV self-sampling.
What's Your Reaction?
